title: Quality of life measures as a preliminary clinical indicator in patients with primary brain tumors.
abstract: BACKGROUND
  The health-related quality of life (HRQOL) measures serve as valuable indicators of survival in patients with newly diagnosed primary brain tumors (PBTs). HRQOL outcomes may benefit clinical decision-making by individualizing patient treatment and improving communications between the doctor, patient, and families. Exploring the individual items of the European Organization and Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QOL) measures may be predictive of prognosis.
  
  
  METHODS
  We prospectively collected the validated HRQOL and standard clinical and radiological measures from 48 patients with newly diagnosed PBT. The patients were followed every 3 months over 2 years. No proxies were allowed. Questionnaire responses were compared between two groups: Patients with recurrence and/or death (n = 26) and patients without a recurrence (n = 22). A total of 17 patients succumbed to a tumor-related death. Statistical analysis utilizing nonparametric t-tests and Wilcoxon sign tests assessed QOL responses.
  
  
  RESULTS
  Significant group differences were noted in the QOL measures with more negative responses in the recurrence group. EORTC QLQ-C30 questions revealed a poor global HRQOL scale (P < 0.005) and pain interfering with daily activities (P < 0.05). EORTC QLQ-BN20 questions revealed weakness of the legs (P < 0.05), coordination difficulties (P < 0.005), and unsteady gait (P < 0.05). Hospital Anxiety and Depression Scale (HADS) questions reflected a patient who is slowed down (P < 0.01) and "frightened" (P < 0.05).
  
  
  CONCLUSIONS
  Our analysis of longitudinal HRQOL measures may shed light on the prognostic significance of HRQOL measures in patients with newly diagnosed PBT. Further research is warranted to determine which selected individual measures of the EORTC QOL measures may be predictive of a patient's progression-free and overall survival and to test their validity and reliability in clinical trials.
authors: Norton Neuroscience Institute and Norton Cancer Institute, Norton Healthcare, Louisville, KY 40202, USA.
authors: Lisa B E
authors: LB
authors: Shields
authors: Aliisha
authors: A
authors: Choucair
authors: Ali K
authors: AK
authors: Choucair
keywords: Brain tumor; malignant; prognostic factor; quality of life
references: Oncologist. 2010;15(6):618-26
references: 20507891
references: J Neurooncol. 2009 Dec;95(3):413-419
references: 19548070
references: Psychooncology. 2011 Oct;20(10):1102-7
references: 20737644
references: J Neurooncol. 2009 Nov;95(2):247-257
references: 19533025
references: Acta Psychiatr Scand. 1983 Jun;67(6):361-70
references: 6880820
references: Coll Antropol. 2010 Mar;34 Suppl 1:93-7
references: 20402303
references: BMC Cancer. 2011 Aug 15;11:353
references: 21843358
references: J Clin Oncol. 2009 Dec 1;27(34):5816-22
references: 19858383
references: Neurosurgery. 2005 Sep;57(3):495-504; discussion 495-504
references: 16145528
references: J Neurooncol. 2011 May;103(1):129-36
references: 20820874
references: Mayo Clin Proc. 2007 Oct;82(10):1214-28
references: 17908528
references: Br J Cancer. 2010 Apr 27;102(9):1341-7
references: 20389302
references: J Neurosurg. 2000 Dec;93(6):917-26
references: 11117863
references: J Clin Oncol. 2006 Aug 1;24(22):3636-43
references: 16877731
references: Int J Radiat Oncol Biol Phys. 1997 Apr 1;38(1):9-20
references: 9211998
references: J Clin Oncol. 2008 Mar 10;26(8):1355-63
references: 18227528
references: J Clin Psychiatry. 1990 Jun;51(6):239-42
references: 2347861
references: J Clin Oncol. 2007 Dec 20;25(36):5731-7
references: 18089867
references: J Neurosurg. 2011 Jun;114(6):1622-30
references: 21314270
references: J Neurotrauma. 2012 Apr 10;29(6):1029-37
references: 22111890
references: J Psychosom Res. 2002 Feb;52(2):69-77
references: 11832252
references: J Neurosurg. 2001 Aug;95(2):190-8
references: 11780887
references: Neuro Oncol. 2009 Feb;11(1):41-50
references: 18628405
references: Oncologist. 2011;16 Suppl 2:23-31
references: 21346037
references: Indian J Cancer. 2011 Jan-Mar;48(1):55-9
references: 21248445
references: Br J Cancer. 2007 Aug 6;97(3):302-7
references: 17609661
references: Ann Oncol. 2006 Nov;17(11):1698-704
references: 16968876
references: N Engl J Med. 1996 Mar 28;334(13):835-40
references: 8596551
references: Ann Oncol. 2006 Jul;17(7):1037-8
references: 16766590
references: Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):71-8
references: 18164829
references: BMC Cancer. 2010 Jun 18;10:305
references: 20565883
references: Eur Arch Psychiatry Clin Neurosci. 2006 Dec;256(8):516-21
references: 16960653
references: Neuro Oncol. 2009 Feb;11(1):59-68
references: 18713953
references: Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):179-96
references: 20528407
references: Neuro Oncol. 2009 Feb;11(1):51-8
references: 18617599
references: N Engl J Med. 2005 Mar 10;352(10):987-96
references: 15758009
references: J Psychosom Res. 1997 Jan;42(1):17-41
references: 9055211
references: JAMA. 2005 Feb 2;293(5):557-64
references: 15687310
references: Semin Oncol. 2004 Oct;31(5):635-44
references: 15497116
references: Br J Cancer. 2010 Oct 26;103(9):1318-24
references: 20877359
references: Eur J Cancer. 2010 Apr;46(6):1033-40
references: 20181476